Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genmab A/S (GMAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Genmab files annual reports on Form 20‑F and furnishes current reports on Form 6‑K under the Securities Exchange Act of 1934. These filings cover a wide range of topics, from interim financial results and capital increases to equity awards, articles of association and material company announcements.
Recent Forms 6‑K referenced in the available data include interim reports, company announcements about net sales of partnered products such as DARZALEX, capital increases resulting from employee warrant exercises, grants of restricted stock units and warrants, and disclosures related to the proposed acquisition of Merus N.V. and associated financing. Other 6‑K filings incorporate company announcements on regulatory milestones for EPKINLY (epcoritamab‑bysp), portfolio prioritization decisions and updates on late‑stage clinical programs.
Because Genmab uses its 6‑K reports to furnish key announcements to U.S. investors, these filings can be a primary source for understanding changes in its capital structure, details of tender offers and acquisitions, and the status of important clinical and commercial programs. On Stock Titan, users can review these documents alongside AI‑powered summaries that explain the context and main points of each filing, helping to interpret technical content in forms such as 6‑K and 20‑F.
Investors researching GMAB can use this page to follow how Genmab reports on its antibody platforms, collaborations, late‑stage pipeline, financing arrangements and governance documents over time. The combination of real‑time EDGAR updates and AI‑generated insights is intended to make it easier to navigate lengthy filings and identify information relevant to Genmab’s business and capital markets activity.
Genmab A/S filed a Form 6-K as a foreign private issuer for September 2025. The filing notes that a company announcement dated September 26, 2025 covers the grant of restricted stock units and warrants to employees of Genmab.
The Form 6-K is deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related registrations from the filing date, unless later superseded by other filings.
Genmab A/S has furnished a Form 6-K for September 2025 that attaches two exhibits related to a major shareholder. The exhibits are a company announcement dated September 23, 2025 and a standard notification of major holdings. The filing is incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S submitted a Form 6-K for September 2025 that attaches two company announcements dated September 9, 2025. One announcement describes a capital increase in Genmab resulting from employee warrant exercises. The other details transactions in Genmab shares and linked securities by managerial employees and their closely associated persons.
The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, making these announcements part of those share-based compensation plans’ disclosure record.
Genmab A/S filed a Form 6-K as a foreign private issuer for August 2025. The report primarily forwards an attached company announcement describing a capital increase in Genmab resulting from the exercise of employee warrants. The filing also specifies that this 6-K is incorporated by reference into several existing Genmab Form S-8 registration statements covering employee equity compensation plans.
Genmab’s H1-25 6-K shows solid growth and an upgraded FY-25 outlook. Revenue climbed 19 % YoY to $1.64 bn on stronger DARZALEX (+22 % J&J sales), Kesimpta and EPKINLY. Royalty income rose 24 % to $1.38 bn, representing 84 % of total revenue. Operating profit increased 56 % to $548 m as costs grew only 6 %, expanding the margin to 33 %. Net profit reached $531 m.
Liquidity remains robust with $1.30 bn cash and $1.60 bn marketable securities; equity ratio is 82 %. Functional and presentation currency switched to USD on 1 Jan 25.
Revised 2025 guidance: revenue $3.5-3.7 bn (mid-point +$100 m), operating profit $1.055-1.405 bn (mid-point +$100 m); operating-expense range unchanged.
Operational highlights: sBLA filed for epcoritamab+R2 in r/r FL; Tivdak launched in Japan; Rina-S posted 50 % ORR in endometrial cancer; >40 epcoritamab abstracts presented. Workforce up to 2,639 FTEs.
Risks & negatives: TEPEZZA royalties -8 %; lower reimbursement revenue; ongoing Chugai patent suit and AbbVie trade-secret litigation; FX gains moderated after USD switch.